Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib + R-CHOP in Newly Diagnosed High Risk DLBCL
NCT04323956Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of parsaclisib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Mayo Clinic. Primary endpoints: Maximum tolerated dose up to 21 days and Complete metabolic response rate. Started Jun 2020; status: active, not recruiting.
02
Drugs
parsaclisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04323956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04323956.